Anti-drug vaccines
AssigneeThe Trustees of Columbia University in the City of New York
InventorsShi-Xian Deng, Donald W. Landry, Gavreel Kalantarov, Trakht Ilya
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.
Claims13
An isolated conjugate formed between a human serum albumin self-protein and a cocaine pre-hapten having Formula II:
- wherein R1 and R2 are the same or different, and is:
- unsubstituted or substituted, branched or unbranched, alkyl;
- or
- unsubstituted or substituted, branched or unbranched, alkoxy.
A pharmaceutical composition comprising a cocaine/human serum albumin self-protein conjugate in an amount effective at inducing a therapeutic immune response to cocaine in an immunocompetent subject, together with a suitable pharmaceutical carrier, wherein the pharmaceutical composition comprises a compound having Formula III:
- where R is CH3 and R1 is O-protein, wherein the protein is human serum albumin self-protein, and wherein the protein is directly conjugated to R1.
A pharmaceutical composition comprising a cocaine/human serum albumin self-protein conjugate in an amount effective at inducing a therapeutic immune response to cocaine in an immunocompetent subject, together with a suitable pharmaceutical carrier, wherein the pharmaceutical composition comprises a compound having Formula III:
- where R1 is O—CH3 and R2 is selected from the group consisting of tether protein and protein, where the protein is human serum albumin self-protein.
Dependencies are inferred from the claim text.